PRA Health Sciences recruited a healthcare marketing firm with the goal of refining its pitch to potential trial participants and improving recruitment.
Lux Ventures and a joint venture between Novartis and Qualcomm are investing $6.5 million into Science 37, an upstart company that promises to make clinical trials more efficient by uniting stakeholders.
Icon, at work on new approaches to educating potential study participants, launched a new technology designed to inform patients of the possible risks and benefits of a clinical trial before they meet with a physician.
CRO giant Parexel International has expanded its Rolodex of clinical trial sites to more than 180 around the world, a network the company says allows it to more quickly find patients for studies.
London startup TrialReach hauled in $13.5 million in Series B cash, funds that will help expand its technology designed to connect patients with their ideal clinical trials.
With pharma companies fretting about the cost of co-developing biomarkers for cancer drugs during early development, Merck staffers have proposed a novel solution: Pay for patients to have their tumors sequenced. Survey data suggest patients are open to the idea.
Trialbee, a Swedish patient-recruitment outfit, has added AstraZeneca to its client roster, bringing its direct-to-patient technology to the U.K. drugmaker.
Trialbee has added another large pharma to its list of clients, with AstraZeneca following Novo Nordisk in signing up to work with the online trial recruitment specialist. The AstraZeneca deal spans multiple regions, therapeutic areas and phases of clinical trials.
Mayo Clinic and IBM have teamed up to apply cutting-edge technology to the age-old problem of enrolling patients into clinical trials. Starting next year Mayo Clinic will use IBM's supercomputer Watson to automatically match patients to clinical trials.
Global CRO INC Research has teamed up with a trade group of clinical research sites, lending its expertise in an effort to better integrate sponsors, CROs and investigators in the R&D process.